Sanofi Inks $480M Deal with Nurix for Novel Transcription Factor Degrader Targeting Autoimmune Disease

April 2, San Francisco, focused on targetedProtein Degradation DrugsA clinical-stage biopharmaceutical company focused on the discovery, development, and commercializationNurix Therapeutics Announcement of Exclusive Authorization to Sanofi for an Undisclosed Nurix Pipeline, the pipeline targets a previously undruggable transcription factor associated with autoimmune diseases. The undisclosed target is a central regulator of inflammatory responses and differs from the previously disclosed STAT6 degrader.

"Using our DEL-AI platform, we successfully identified new binders, from which we derived a series of targeted protein degraders and standalone targeted binders for this previously undruggable target. This high-value target is a transcription factor involved in regulating the transcription of pro-inflammatory cytokines, acting as a central regulator in the inflammatory response of autoimmune diseases. Targeted protein degradation can provide an innovative therapeutic option."

"Sanofi's commitment to this program expands our co-discovery pipeline in autoimmune diseases and demonstrates the productivity of our collaboration. Furthermore, the high novelty of this target further validates the power of Nurix's DEL-AI discovery platform in driving the discovery and development of truly innovative drugs. Partnerships are a key component of Nurix's business model, and retaining product options in the U.S. adds non-dilutive capital while expanding our pipeline. To date, Nurix has received $460 million from partners, including $105 million from its collaboration with Sanofi. We look forward to continuing to advance these programs with the shared goal of providing new treatment options for patients with autoimmune and inflammatory diseases."

According to the cooperation agreement, Nurix is deploying its proprietary DEL-AI drug discovery platform to identify novel drugs that use E3 ligases to induce the degradation of specific drug targets. Sanofi has the right to license the candidate drugs generated from this work, and Nurix has the option to co-develop and co-promote up to two future products in the United States after the research phase to evaluate dosage, efficacy, and safety, providing clinical proof of concept. For projects Nurix chooses to co-develop and co-promote, both parties will equally share profits and losses in the U.S., and Nurix will be eligible for royalties on sales of all optional products outside the U.S. For projects where Nurix does not exercise its option, Nurix will receive milestones and royalties based on global development and sales. Following the signing of the agreement in December 2019, Sanofi paid Nurix an upfront payment of $55 million, followed by an additional $22 million a year later to expand the scope of the collaboration. Including this $15 million license extension fee, as part of this collaboration, Nurix has received $105 million from Sanofi, and each licensed program remains eligible for up to $465 million in development, regulatory, and commercial milestones, as well as future sales royalties.

Exciting Live Broadcast Preview

Press and hold to scan the QR code and participate immediately ↓

Recommendation 1

April 18 (Friday) 15:00-16:00

Exploration of Upstream Cultivation Processes in CGT: How to Address Long Development Cycles/Low Yields/High Costs?

In Collaboration with 医麦客 IBI EXPO 2026

Dian Dian "Share”、“Like" and "In View", charge me up a bit~"